
Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
About this episode
In part two of this two-part episode, Bernie Marini and Anthony Perissinotti discuss the use of rituximab in acute lymphoblastic leukemia (ALL), based on the recent publication of the UKALL14 study (Marks, et al. Lancet Haematol, 2022): https://pubmed.ncbi.nlm.nih.gov/35358441/. We also discuss the previously published GRAALL study that evaluated rituximab in ALL (Maury, et al. NEJM, 2016, https://pubmed.ncbi.nlm.nih.gov/27626518/), and what we can conclude from the literature to date. The data surprises us, and makes us question our own practices!
Get every episode summarized
Each time WolverHeme Happy Hour publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from WolverHeme Happy Hour

VAR Review with Dr. Bixby: Reversing the Call on MPAL
WolverHeme Happy Hour

Bispecifics ate CAR-T's lunch: a multiple myeloma debate
WolverHeme Happy Hour

Episode 47: Cult-Like Thinking in BMT
WolverHeme Happy Hour

Spring Cleaning the Evidence from ASH 2025 with Common Sense Oncology
WolverHeme Happy Hour